Retatrutide mimics the action of three hormones: GLP-1, GIP, and glucagon. Eli Lilly is calling it triple G. Meanwhile, the ...

Boston Scientific Corp.’s OPTION study demonstrated left atrial appendage closure with the Watchman Flx device reduced risk of stroke compared to management with direct oral anticoagulants or warfarin ...

"Metformin was associated with a lowered risk of asthma attacks by approximately 30%," the researchers found. When patients ...

“Madrigal is doing a lot of work for us,” said Frederic Cren, CEO of Inventiva Pharma, which has its own oral MASH drug ...

Ethics Board Approval Granted for Lexaria Receives Ethics Board Approval for 12-Week Phase 1b DehydraTECH GLP-1 Study in ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

The best online providers offer strong support services to help you succeed in your GLP-1 weight loss journey.

Lower Manhattan-based Metsera is one of the latest drug startups to throw its hat into the ring with the pharma giants ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

Waystar upped its 2024 outlook and now expects total revenue to range between $926 million and $934 million, compared to ...

The following is a summary of "Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide ...